Dehydroepiandrosterone induces growth arrest of hepatoma cells via alteration of mitochondrial gene expression and function

International Journal of Oncology

Volumn 33, Issue 5, 2008, Pages 969-977

  Ho, Hung Yao ^a   Cheng, Mei Ling ^a,b   Chiu, Hsin Yu ^a   Weng, Shiue Fen ^a   Chiu, Daniel Tsun Yee ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Hepatoma; Mitochondrion; Steroid

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVALONIC ACID; PRASTERONE; PYRUVIC ACID; MITOCHONDRIAL DNA;

ARTICLE; CELL CYCLE ARREST; CELL NUCLEUS; CELL STRAIN HEPG2; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; ENZYME ACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE STRUCTURE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOCHONDRIAL GENE; MITOSIS INHIBITION; PRIORITY JOURNAL; CELL PROLIFERATION; ENERGY METABOLISM; GENETICS; LIVER TUMOR; METABOLISM; MITOCHONDRION; PATHOLOGY; TIME;

ADENOSINE TRIPHOSPHATE; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DEHYDROEPIANDROSTERONE; DNA, MITOCHONDRIAL; ENERGY METABOLISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSEPHOSPHATE DEHYDROGENASE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; LIVER NEOPLASMS; MITOCHONDRIA; PYRUVIC ACID; TIME FACTORS;

EID: 58149178067     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000084     Document Type: Article

References (54)

1. Parker CR Jr: Dehydroepiandrosterone and dehydroepiandrosterone sulfate production in the human adrenal during development and aging. Steroids 64: 640-647, 1999.
2. Yen SC and Laughlin GA: Aging and the adrenal cortex. Exp Gerontol 33: 897-910, 1998.
3. Cleary MP: The antiobesity effects of dehydroepiandrosterone in rats. Proc Soc Exp Biol Med 196: 8-16, 1991.
4. Mcintosh MK and Berdanier CD: Antiobesity effects of dehydroepiandrosterone are mediated by futile substrate cycling in hepatocytes of BHE/cdb rats. J Nutr 121: 2037-2043, 1991.
5. Coleman DL, Leiter EH and Schwizer RW: Therapeutic effects of dehydroepiandrosterone in diabetic mice. Diabetes 31: 830-833, 1982.
6. Coleman DL, Schwizer RW and Leiter EH: Effect of genetic background on the therapeutic effects of dehydroepiandrosterone in diabetes-obesity mutants and in aged normal mice. Diabetes 33: 26-32, 1984.
7. Gordon GB, Bush DE and Weisman HF: Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury. J Clin Invest 82: 712-720, 1988.
8. Nafziger AN, Herrington DM and Bush TL: Dehydroepiandrosterone and dehydroepiandrosterone sulfate: their relation to cardiovascular disease. Epidemiol Rev 13: 267-293, 1991.
9. Wojtal K, Trojnar MK and Czuczwar SJ: Endogenous neuroprotective factors: neurosteroids. Pharmacol Rep 58: 335-340, 2006.
10. Zumoff B, Levin J, Rosenfeld RS, Markham M, Strain GW and Fukushima DK: Abnormal 24-h mean plasma concentrations of dehydroepiandrosterone and dehydroepiandrosterone sulfate in women with primary operable breast cancer. Cancer Res 41: 3360-3363, 1981.
11. Gordon GB, Helzlsouer KJ and Comstock GW: Serum levels of dehydroepiandrosterone and its sulfate and the risk of developing bladder cancer. Cancer Res 51: 1366-1369, 1991.
12. Hursting SD, Perkins SN, Haines DC, Ward JM and Phang JM: Chemoprevention of spontaneous tumorigenesis in p53-knockout mice. Cancer Res 55: 3949-3953, 1995.
13. Moore MA, Thamavit W, Ichihara A, Sato K and Ito N: Influence of dehydroepiandrosterone, diaminopropane and butylated hydroxyanisole treatment during the induction phase of rat liver nodular lesions in a short-term system. Carcinogenesis 7: 1059-1063, 1986.
14. Garcea R, Daino L, Pascale R, Frassetto S, Cozzolino P, Ruggiu ME and Feo F: Inhibition by dehydroepiandrosterone of liver preneoplastic foci formation in rats after initiation-selection in experimental carcinogenesis. Toxicol Pathol 15: 164-169, 1987.
15. Simile M, Pascale RM, De Miglio MR, Nufris A, Daino L, Seddaiu MA, Muroni MR, Rao KN and Feo F: Inhibition by dehydroepiandrosterone of growth and progression of persistent liver nodules in experimental rat liver carcinogenesis. Int J Cancer 62: 210-215, 1995.
16. Nyce JW, Magee PN, Hard GC and Schwartz AG: Inhibition of 1,2-dimethylhydrazine-induced colon tumorigenesis in Balb/c mice by dehydroepiandrosterone. Carcinogenesis 5: 57-62, 1984.
17. Schwartz AG and Tannen RH: Inhibition of 7,12-dimethylbenz-[a]-anthracene- and urethane-induced lung tumor formation in A/J mice by long term treatment with dehydroepiandrosterone. Carcinogenesis 2: 1335-1337, 1981.
18. Ratko TA, Detrisac CJ, Mehta RG, Kelloff GJ and Moon RC: Inhibition of rat mammary gland chemical carcinogenesis by dietary dehydroepiandrosterone or a fluorinated analogue of dehydroepiandrosterone. Cancer Res 51: 481-486, 1991.
19. Melvin WS, Boros LG, Muscarella P, Brandes JL, Johnson LA, Fisher WE, Schirmer WJ and Ellison EC: Dehydroepiandrosterone-sulfate inhibits pancreatic carcinoma cell proliferation in vivo and in vivo. Surgery 121: 392-397, 1997.
20. Rao MS and Subbarao V: Dehydroepiandrosterone inhibits DNA synthesis of rat hepatocytes induced by partial hepatectomy or mitogen (ciprofibrate). Cell Prolif 30: 1-5, 1997.
21. Tian WN, Braunstein LD, Pang J, Stuhlmeier KM, Xi QC, Tian X and Stanton R: Importance of glucose-6-phosphate dehydrogenase activity for cell growth. J Biol Chem 273: 10609-10617, 1998.
22. Boccuzzi G, Di-Monaco M, Brignardello E, Leonardi L, Gatto V, Pizzini A and Gallo M: Dehydroepiandrosterone antiestrogenic action through androgen receptor in MCF-7 human breast cancer cell line. Anticancer Res 13: 2267-2272, 1993.
23. Yoshida S, Honda A, Matsuzaki Y, Fukushima S, Tanaka N, Takagiwa A, Fujimoto Y, Miyazaki H and Salen G: Antiproliferative action of endogenous dehydroepiandrosterone metabolites on human cell lines. Steroids 68: 73-83, 2003.
24. Biaglow JE, Ayene IS, Koch CJ, Donahue J, Stamato TD and Tuttle SW: G6PD-deficient cells and the bioreduction of disulfides:effects of DHEA, GSH depletion and phenylarsine oxide. Biochem Biophys Res Commun 273: 846-852, 2000.
25. Ng HP, Wang YF, Lee CY and Hu ML: Toxicological and antioxidant effects of short-term dehydroepiandrosterone injection in young rats fed diets deficient or adequate in vitamin E. Food Chem Toxicol 37: 503-508, 1999.
26. Pascale RM, Simile MM, De Miglio MR, Nufris A, Seddaiu MA, Muroni MR, Danni O, Rao KN and Feo F: Inhibition of 3-hydroxy-3-methyl glutaryl-CoA reductase activity and gene expression by dehydroepiandrosterone in preneoplastic liver nodules. Carcinogenesis 16: 1537-1542, 1995.
27. Schulz S, Klann RC, Schonfeld S and Nyce JW: Mechanisms of cell growth inhibition and cell cycle arrest in human colonic adenomas cells by dehydroepiandrosterone: role of isoprenoid biosynthesis. Cancer Res 52: 1372-1376, 1992.
28. Aoki K, Saito T, Satoh S, Mukasa K, Kaneshiro M, Kawasaki S, Okamura A and Sekihara H: Dehydroepiandrosterone suppresses the elevated hepatic glucose-6-phosphatase and fructose-1,6-bisphosphatase activities in C57BL/Ksj-db/db mice. Comparison with Troglitazone. Diabetes 48: 1579-1585, 1999.
29. Yamashita R, Saito T, Satoh S, Aoki K, Kaburagi Y and Sekihara H: Effects of dehydroepiandrosterone on gluconeogenic enzymes and glucose uptake in human hepatoma cell line. Endocrine J 52: 727-733, 2005.
30. Nakashima N, Haji M, Sakai Y, Ono Y, Umeda F and Nawata H: Effect of dehydroepiandrosterone on glucose uptake in cultured human fibroblasts. Metabolism 44: 543-548, 1995.
31. Borenfreund E and Puerner JA: Toxicity determined in vivo by morphological alterations and neutral red absorption. Toxicol Lett 24: 119-124, 1985.
32. Cheng ML, Ho HY, Wu YH and Chiu DTY: Glucose-6-phosphate dehydrogenase-deficient cells show an increased propensity for oxidant-induced senescence. Free Radic Biol Med 36: 580-591, 2004.
33. Ho HY, Cheng ML, Cheng PF and Chiu DTY: Low oxygen tension alleviates oxidative damage and delays cellular senescence in G6PD-deficient cells. Free Radic Res 41: 571-579, 2007.
34. Cheng ML, Ho HY, Huang YW, Lu FJ and Chiu DTY: Humic acid induces oxidative DNA damage, growth retardation, and apoptosis in human primary fibroblasts. Exp Biol Med 228: 413-423, 2003.
35. Chen PL, Scully P, Shew JY, Wang JY and Lee WH: Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 58: 1193-1198, 1989.
36. Xu D and Finkel T: A role for mitochondria as potential regulators of cellular life span. Biochem Biophys Res Commun 294: 245-248, 2002.
37. Wilson L, Yang Q, Szustakowski JD, Gullicksen PS and Halse R: Pyruvate induces mitochondrial biogenesis by a PGC-1α-independent mechanism. Am J Physiol Cell Physiol 292: C1599-C1605, 2007.
38. Raineri R and Levy HR: On the specificity of steroid interaction with mammary glucose-6-phosphate dehydrogenase. Biochemistry 9: 2233-2243, 1970.
39. Gordon G, Mackow MC and Levy HR: On the mechanism of interaction of steroids with human glucose-6-phosphate dehydrogenase. Arch Biochem Biophys 318: 25-29, 1995.
40. Schwartz AG and Pashko LL: Mechanism of cancer preventive action of DHEA: role of glucose-6-phosphate dehydrogenase. Ann NY Acad Sci 774: 180-186, 1995.
41. Gordon GB, Newitt JA, Shantz LM, Weng DE and Talalay P: Inhibition of the conversion of 3T3 fibroblast clones to adipocytes by dehydroepiandrosterone and related anticarcinogenic steroids. Cancer Res 46: 3389-3395, 1986.
42. Matsuzaki Y and Honda A: Dehydroepiandrosterone and its derivative: potentially novel anti-proliferative and chemopreventive agents. Curr Pharm Des 12: 3411-3421, 2006.
43. Karbowski M and Youle RJ: Dynamics of mitochondrial morphology in healthy cells and during apoptosis. Cell Death Differ 10: 870-880, 2003.
44. Polyakov VY, Soukhomlinova MY and Fais D: Fusion, fragmentation, and fission of mitochondria. Biochemistry (Mosc) 68: 838-849, 2003.
45. Stevens BJ: Variation in number and volume of the mitochondria in yeast according to growth conditions. A study based on serial sectioning and computer graphics reconstitution. Biol Cell 28: 37-56, 1977.
46. Margineantu DH, Cox WG, Sundell L, Sherwood SW, Beechem JM and Capaldi RA: Cell cycle dependent morphology change and associated mitochondrial DNA redistribution in mitochondria of human cell lines. Mitochondrion 1: 425-435, 2002.
47. Chen H and Chan DC: Emerging functions of mammalian mitochondrial fusion and fission. Hum Mol Genet 14: R283-R289, 2005.
48. Safiulina D, Peet N, Seppet E, Zharkovsky A and Kaasik A: Dehydroepiandrosterone inhibits complex of the mitochondrial respiratory chain and is neurotoxic in vivo and in vivo. Toxicol Sci 93: 348-356, 2006.
49. Mohan PF and Cleary MP: Dehydroepiandrosterone and related steroids inhibit mitochondrial respiration in vivo. Int J Biochem 21: 1103-1107, 1989.
50. Katyare SS, Modi HR and Patel MA: Dehydroepiandrosterone treatment alters lipid/phospholipid profiles of rat brain and liver mitochondria. Curr Neurovasc Res 3: 273-279, 2006.
51. Swierczynski J and Mayer D: Dehydroepiandrosterone-induced lipid peroxidation in rat liver mitochondria. J Steroid Biochem Mol Biol 58: 599-603, 1996.
52. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR and Lampidis TJ: 2-Deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 64: 31-34, 2004.
53. Geschwind JFH, Ko YH, Torbenson MS, Magee C and Pedersen PL: Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62: 3909-3913, 2002.
54. Heerdt BG, Houston MA and Augenlicht LH: The intrinsic mitochondrial membrane potential of colonic carcinoma cells is linked to the probability of tumor progression. Cancer Res 65: 9861-9867, 2005.